Active Ingredient
Diphenhydramine HCl 2%
After Bite Xtra
FDA Label NDC 90107-1270
Full FDA labeling including Indications, Dosage, Usage, and Precautions
Structured Product Label
The following Structured Product Label (SPL) was submitted to the FDA by Adventure Ready Brands for the product After Bite Xtra (NDC 90107-1270). This document serves as the official prescribing information, containing essential scientific data and clinical materials required for healthcare providers and patients.
This specific version of the label includes detailed information regarding active ingredient, purpose, uses, warnings, do not use, ask a doctor before use, when using, stop use and ask a doctor if, and other regulatory disclosures. Use the navigation below to review specific sections of the FDA submission.
Label Section Quick Index
Purpose
Topical Analgesic
Uses
For the temporary relief of pain and itching associated with
- minor burns
- minor cuts
- scrapes
- insect bites
- minor skin irritations
- rashes due to poison ivy, poison oak, and poison sumac
Warnings
For external use only
Do Not Use
Do not use
- on large areas of the body
- with any other product containing diphenhydramine, even one taken by mouth
Ask A Doctor Before Use
Ask a doctor before use
- on chicken pox
- on measles
When Using
When using this product avoid contact with eyes.
Stop Use And Ask A Doctor If
Stop use and ask a doctor if
- condition worsens
- if symptoms persist for more than 7 days or clear up and occur again within a few days
Keep Out Of Reach Of Children
Keep out of reach of children. If swallowed, get medical help or contact a Poison Control Center right away.
Directions
Directions
- do not use more than directed
- adults and children over 2 years of age and older: apply to affected area not more than 3 to 4 times daily
- children under 2 years of age: ask a doctor
Inactive Ingredients
Aloe Vera, Citric Acid, Ethyl Alcohol, Glycerin, Methocel, Methylparaben, Oat Beta Glucan, Propylparaben, Purified Water, Sodium Hydroxide, Tea Tree Oil, Vitamin E
* Please review the disclaimer below.
